Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 190OTHER 26NIH 6OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 18Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 89Lung Neoplasms 78Small Cell Lung Carcinoma 28Adenocarcinoma of Lung 8Mesothelioma, Malignant 6Esophageal Neoplasms 6Carcinoma, Hepatocellular 4Adenocarcinoma 4Stomach Neoplasms 3Neoplasm Metastasis 3NSCLC 3Motor Activity 3Mesothelioma 3Meningeal Carcinomatosis 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Thymoma 2Sarcopenia 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Melanoma 2Lung Diseases 2EGFR Positive Non-small Cell Lung Cancer 2Disease 2Colorectal Neoplasms 2Weight Loss 1Untreated Advanced Non-small Cell Lung Cancer 1Unresectable Non-small Cell Lung Cancer 1

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Triple Negative Breast Neoplasms × Thoracic × Clear all
NCT04142931 2021-03-24

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Sheba Medical Center

Phase 1 Unknown
30 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡